(Circulation. 1999;99:659-665.)
© 1999 American Heart Association, Inc.
Clinical Investigation and Reports |
From the Department of Cardiology, Chang Gung University, and Chang Gung Memorial HospitalLinkou, Taiwan.
Correspondence to Chi-Tai Kuo, MD, Chang Gung Memorial Hospital, 199 Tun Hwa N Rd, Taipei, Taiwan. E-mail chitai{at}adm. cgmh.com.tw
| Abstract |
|---|
|
|
|---|
Methods and ResultsThis study was composed of 33 patients with typical AVNRT and continuous AVN conduction curves (group 1) and 103 patients with AVNRT and discontinuous AVN conduction curves (group 2). Using A1A2A3 with predefined fast pathwayconducted A2, we examined the effects of slow pathway ablation on the A2A3/A3H3 curves in both groups. In group 1, anterograde AVN effective refractory period (272±33 versus 277±47 ms, P>0.05) and AVN Wenckebach block cycle length (320±45 versus 343±59 ms, P>0.05) remained unchanged after ablation. A2H2max was shorter in group 1 than group 2 (237±89 versus 395±72 ms, P<0.05) at baseline. It shortened in group 2 (395±72 versus 221±78 ms, P<0.001) but remained unchanged in group 1 (237±89 versus 214±59 ms, P>0.05) after ablation. A1A2A3 could further disclose discontinuous A2A3/A3H3 curves in 29 patients of group 1. A3H3max shortened in both groups (375±81 versus 238±82 ms, P<0.001, and 419±104 versus 220±78 ms, P<0.001, respectively) in a similar fashion. Successful ablation resulted in loss of the left portion of the A2A3/A3H3 curves in the 4 patients of group 1 with continuous A2A3/A3H3 curves.
ConclusionsUse of A1A2A3 could expose discontinuous A2A3/A3H3 curves in most patients with continuous A1A2/A2H2 curves. Significant shortening of A3H3max after ablation may be indicative of successful elimination of AVNRT.
Key Words: atrioventricular node catheter ablation tachycardia electrophysiology
| Introduction |
|---|
|
|
|---|
| Methods |
|---|
|
|
|---|
Electrophysiological Study
Informed consent for the study and ablation was obtained from
all patients. Each patient was studied in the postabsorptive state
without sedation. All antiarrhythmic drugs were discontinued for at
least 5 half-lives before the study.11 12 Multipolar
electrode catheters were positioned in the coronary sinus, high
right atrium, His bundle, and right ventricular apex. The
decapolar electrode catheter in the coronary sinus had its most
proximal electrode pair positioned just inside the ostium. Intracardiac
electrograms from the high right atrium, His bundle, and
coronary sinus electrodes, along with ECG leads I, aVF, and
V1, were continuously recorded (EP
Laboratory, Biomedical Instrumentation, Inc and
Catheterization2000 Crossover System, Gould, Inc).
Programmed electrical stimulation (model DTU-215, Bloom Associates,
Ltd) was delivered by use of 2-ms rectangular impulses at twice the
late diastolic pacing threshold. All intracardiac
electrograms were bandpass-filtered between 40 and 500 Hz. Briefly, the
stimulation protocol consisted of high right atrial and right
ventricular incremental pacing to block and extrastimulus
testing with at least 2 driven cycle lengths (usually 600 and 400 ms).
The initiation of typical AVNRT was generally associated with a
discontinuous
A1A2/A2H2
curve.6 11 12
A1A2A3 was then performed by use of predetermined fast pathwayconducted A2 (A1A2 usually at 50 to 100 ms greater than the effective refractory period [ERP] of AVN or fast pathway with an A2H2 <180 ms), namely fast pathwaycoupled A1A2A3 in both groups. We always checked the atrial-His bundle (AH) during induction of single AVN echo or induction and maintenance of the AVNRT to determine that the predefined A2 and thus A2H2 did not fall into the slow pathway range. The first of 2 premature beats was called the conditioning beat. The test beats, labeled A3, were introduced with progressively shorter A2A3, starting from 600 ms in steps of 10 ms, until the ERP of AVN or the atrium was reached8 in each stimulating cycle. The A2A3/A3H3 curve was then constructed. The examination of a given patient was performed with stimulation from the same pacing sites during different protocols.
Endocardial Mapping and Radiofrequency Ablation
All patients underwent ablation through the posterior
approach.6 13 14 15 16 17 Three zones within the triangle of Koch
along the tricuspid annulus were arbitrarily defined, including the
anterior third, middle third, and posterior third regions between the
His-bundle recording site and coronary sinus ostium.
These regions were further divided into 2 subsections, the anterior-2
(A2) and anterior-1 (A1), middle-2 (M2) and middle-1 (M1), and
posterior-2 (P2) and posterior-1 (P1), respectively. The orifice
of the coronary sinus was demarcated by coronary sinus
venography. A 7F quadripolar deflectable catheter (Mansfield
Scientific) with a 4-mm tip electrode was used for mapping and
ablation. A radiofrequency generator (RFG-3C, Radionics) was used to
deliver energy at a power setting of 30 W for 30 seconds during each
attempt. Application of energy was interrupted if junctional
tachycardia did not appear within 10 seconds or if
impedance rise, PR prolongation, or AVN block occurred. Lesions were
basically anatomically guided and directed to the posterior, then the
middle, and finally to the anterior area if necessary. The presumed
ablation site was considered optimal if the bipolar electrograms
recorded from the distal electrodes showed an
atrial-to-ventricular electrogram amplitude ratio of 0.1 to
0.5 (usually
0.25).6 11 13 After each application of
energy, the presence or absence of slow pathway conduction and
inducibility of AVNRT was assessed with programmed electrical
stimulation.
The end point of a successful ablation was defined as noninducibility of AVNRT with isoproterenol infusion (at graded doses from 1 to 4 µg/min IV) and/or atropine (0.01 to 0.02 mg/kg IV), even though the residual anterograde slow pathway might be present6 11 13 14 without or with a single AVN echo.
Postablation Electrophysiological Evaluation
All patients underwent repeat testing with single and double
atrial extrastimuli before and during the administration of
isoproterenol and/or atropine, 30 minutes after successful ablation,
and during a later follow-up study at 3 months. All
parameters were measured on the 3 occasions. Each time,
measurements were done during the baseline states.
Definitions
Dual pathway physiology was defined as discontinuous AVN
conduction curves during single atrial extrastimulation. It was
characterized by a
50-ms jump in
A2H2 at a critical range of
A1A2 coupling intervals
(10-ms decrease) during 2 different paced cycle
lengths,1 11 14 resulting in a discontinuity between the
curve to the right of the jump in
A2H2 (fast pathway) and the
portion with the jump (slow pathway). The ERP of the fast pathway was
defined on the basis of discontinuous
A1A2/A2H2
curves. The ERP of the AVN was defined as the longest
A1A2 that failed to result
in an H1-H2 response. In
patients with discontinuous
A1A2/A2H2
curves, the AVN ERP therefore reflects the ERP of the slow pathway; in
those with continuous
A1A2/A2H2
curves, the AVN ERP refers to the shortest ERP. For each patient, the
driven cycle lengths and the coupling intervals of the
A1A2 at which ERP
measurements and
A2A3/A3H3
curves were obtained before ablation were matched and repeated after
ablation. The A2H2max and
A3H3max were defined as the
maximal AH measured during
A1A2 and
A1A2A3,
respectively.
Statistical Analysis
Data were expressed as mean±SD. A repeated-measures
analysis was applied to compare the continuous variables
among 3 consecutive data points before and after ablation.
Multiple-comparison analyses were performed to test the
significance of continuous variables between 2 different groups. A
2 test with Yates' correction or Fisher's
exact test was used to compare the categorical data, and a Student's
t test was performed to compare continuous variables
between groups. A value of P<0.05 was considered
statistically significant.
| Results |
|---|
|
|
|---|
|
|
Effects of Ablation With the Posterior Approach on AVN Conduction
in Group 1
Sustained AVNRT of the slow-fast form was induced in all patients
before ablation. Isoproterenol infusion was required for its initiation
in 12 patients (36%). Definite evidence of dual AVN physiology as
shown by discontinuity of the
A1A2/A2H2
curve was not present in all patients before ablation.
The effects of ablation with the posterior approach on the refractory
period and conduction properties of the AVN are shown in the
Table
. The sinus cycle length (714±191 versus 688±118 ms), AH
(77±18 versus 78±15 ms), AVNWCL (320±45 versus 343±59 ms), and
retrograde AVNWCL (369±125 versus 375±115 ms) remained unchanged
after ablation (P>0.05). Of note, the anterograde
AVN ERP (272±33 versus 277±47 ms, P>0.05) also remained
unchanged after ablation.
A2H2max showed little
change after ablation (237±89 versus 214±59 ms, P>0.05).
Using a predetermined fast pathwayconducted A2,
A1A2A3
was able to further disclose discontinuous
A2A3/A3H3
curves with an A3H3 jump
(
50 ms) in 29 patients (Figures 2
and 3
). Successful ablation resulted in the
loss or marked diminution (Figures 2B
and 3B
) of the
discontinuous
A2A3/A3H3
curve on the left in the former. A lack of discontinuity in the
A2A3/A3H3
curve was seen during 1
A2A3 study in the other 4
patients of group 1 (Figure 4
), in whom
ablation resulted in the loss of the terminal portion of the
A2A3/A3H3
curve on the left. Atrial burst pacing and isoproterenol were required
for the initiation of AVNRT in 3 of these patients. One other patient
required
A1A2A3
to initiate AVNRT. The only parameter that clearly
demonstrated significant change after ablation was the
A3H3max obtained during
A1A2A3
(375±81 versus 238±82 ms, P<0.0001).
|
|
|
Effects of Slow Pathway Ablation on AVN Conduction in Group
2
Sustained typical AVNRT was induced in all patients before
ablation. Isoproterenol infusion was required for the induction in 44
patients (43%). Definite evidence of dual AVN physiology with
discontinuous curves was demonstrated during both
A1A2 and
A1A2A3
in all patients before ablation.
The effects of slow pathway ablation on the refractory period and
conduction properties of the AVN are shown in the Table
. The
sinus cycle length (781±131 versus 752±145 ms), AH (78±19 versus
78±19 ms), AVNWCL (389±76 versus 381±77 ms), and retrograde AVNWCL
(395±106 versus 383±95 ms) remained unchanged after ablation
(P>0.05). The AVN ERP increased (274±45 versus 321±67 ms,
P<0.0001). The ERP of the slow pathway increased (274±45
versus 316±72 ms, P<0.0001), whereas that of the fast
pathway decreased (366±82 versus 339±73 ms, P<0.0001),
thus narrowing the slow pathway window after ablation. All patients
demonstrated discontinuous
A2A3/A3H3
curves with an A3H3 jump
(
50 ms) during
A1A2A3
before ablation. The
A2H2max markedly shortened
after ablation (395±72 versus 221±78 ms, P<0.0001). The
A3H3max also shortened
after ablation (419±104 versus 220±78 ms, P<0.0001).
Successful ablation resulted in the loss or marked diminution of the
slow pathway during both
A1A2 and
A1A2A3.
Comparison of Groups 1 and 2
Before ablation, the sinus cycle length, the anterograde
AVNWCL, and the A2H2max and
A3H3max showed significant
differences (P<0.05) between groups 1 and 2 (Figure 1
). Immediately after ablation, the sinus cycle length, AVN ERP,
and AVNWCL showed significant differences (P<0.05) between
the 2 groups.
Late Electrophysiological Follow-Up at 3 Months
or Later
At late follow-up, the sinus cycle length, anterograde
AVNWCL, and AVN ERP increased from immediate postablation studies in a
similar trend (Figure 5
) in both groups
(Table
). In group 2, the ERP of the slow pathway increased
immediately after ablation (274±45 versus 316±72 ms,
P<0.0001) and increased further (368±78 ms,
P<0.0001) at 3-month follow-up. Conversely, the ERP of the
fast pathway in group 2 shortened (366±82 versus 339±73 ms,
P<0.0001) immediately after ablation but increased in the
long run (406±100 ms, P<0.0001) during the late
follow-up.
|
The baseline AH, retrograde AVNWCL, A2H2max, and A3H3max remained unchanged between the 2 postablation studies in both groups.
As a whole, there were significant differences in the tendency of the series of changes in the electrophysiological variables, including the sinus cycle length, AVN ERP, anterograde AVNWCL, and A2H2max among 3 measurements between the 2 groups (P<0.05, adjusted by age and time).
| Discussion |
|---|
|
|
|---|
A strong correlation between the sinus cycle length, anterograde AVNWCL, and AVN ERP was noted between immediate postablation and late studies for both groups.
Mechanisms of Failure to Demonstrate a Distinct
Discontinuity
Several potential mechanisms may account for the failure to
demonstrate distinct discontinuity in the AVN conduction
(A1A2/A2H2)
curves in otherwise typical AVNRT. Differences in the refractory
periods and conduction properties between the fast and slow pathways
may not be sufficiently distinct at baseline study to yield
discontinuity in the
A1A2/A2H2
curve.1 2 7 It is well known in the electrophysiology
laboratory that discontinuous AVN conduction curves may become
continuous during isoproterenol infusion,3 15 16 17 18 19 20 because
the refractory period of the fast pathway could be abbreviated to the
extent that the slow pathway conduction could not be achieved with
single or even double atrial extrastimuli or with incremental atrial
pacing.
In group 1 patients, A1A2A3 failed to expose the discontinuity of the A2A3/A3H3 curve in a minority of patients. Successful ablation with the posterior approach in these patients resulted in the loss of the tail of the A2A3/A3H3 curve representing the slow pathway. The observation that successful ablation did not produce any changes in the A1A2/A2H2 format is an important and very instructive finding. It indicates that the slow pathway, although present before the ablation, was not detectable in the above format. Conversely, the A2A3/A3H3 format, although not always manifesting the slow pathway by means of a jump, allowed the conclusion that the ablation did affect the slow pathway portion of the conduction curve. However, one cannot conclude from this result that the ablation eliminated the slow pathway. It is quite logical to say that the ablation may have now rendered the slow pathway not detectable in the A2A3/A3H3 format as well. In other words, the elimination of the AVNRT may not necessarily be equaled with elimination of the slow pathway; thus the dual pathway electrophysiology. These findings suggest that the smooth A2A3/A3H3 curve might in fact consist of 2 distinct components, which may be linked to one or the other pathway, respectively. Atrial burst pacing and isoproterenol were required for the initiation of AVNRT in 3 of these patients. One other patient required A1A2A3 to initiate AVNRT. The slow pathway conduction could be achieved in these circumstances to set up for reentry to occur. However, it was difficult to draw any conclusions on the electrophysiological characteristics of the AVN in such a small number of patients.
The anterograde AVN ERP, AVNWCL, and A2H2max remained unchanged in group 1. A3H3max was the only electrophysiological parameter that shortened significantly after successful ablation. To facilitate the ablation procedure, it may be much easier to use A1A2A3 as defined in the report to establish an acceptable therapeutic end point, ie, A3H3max may be a better indicator than A2H2max in determining and confirming the success of the ablation.
Lessons Learned From Ablation
This study further supports the hypothesis that use of
double atrial extrastimulation could reveal distinct discontinuity in
the
A2A3/A3H3
curves in most patients with smooth
A1A2/A2H2
curves. Of note, loss of the terminal portion of the
A2A3/A3H3
curves (to the left of the discontinuity) representing slow
pathway conduction occurred after the elimination of the AVNRT, leaving
a continuous
A2A3/A3H3
curve. At times, the "slow pathway" zone was only modified, leaving
a discontinuous
A2A3/A3H3
curve after elimination of the inducibility of AVNRT. Nonetheless,
A3H3max always shortened in
a significant magnitude. In those who still failed to show
discontinuous
A2A3/A3H3
curves during
A1A2A3,
successful ablation always resulted in the loss or marked diminution of
the terminal portion of the curve on the left, which may be linked to
the slow pathway component.
A3H3max decreased in a parallel fashion after successful ablation in both groups. Both A2H2max and A3H3max were shorter in those with smooth A1A2/A2H2 curves, implying a "less decremental" slow pathway, as suggested by previous studies.2 7 The data suggest that the use of the A2 could increase the difference in conduction time of the fast and slow pathways, although the A2A3/A3H3 curves remained continuous in some patients.
Limitations
In this study, we did not use autonomic blockade to control for
autonomic tone. However, autonomic blockade has been shown not to
affect the observed changes in postablation
refractoriness.19
In our A1A2A3 study, it might be true that neither "A1A2 usually at 50 to 100 ms greater than the ERP of AVN or fast pathway" nor "A2H2 <180 ms" is an indicator of fast pathway conduction. Although we always checked the AH during induction of single AVN echo, induction and maintenance of the AVNRT to determine that the predefined A2 and thus A2H2 did not fall into the slow pathway range. In fact, the predefined A2H2 was most often <150 ms. However, this would not guarantee that slow pathwaycoupled A2 did not occur.
Another potential limitation is the choice of the A2, which may be arbitrary in such a way that A3H3max may not really be the longest attainable interval during A1A2A3. It is also likely that the longest attainable AH interval, AHmax, could be obtained during atrial burst pacing instead of atrial extrastimulation.
We did not routinely use a third drive cycle length to expose discontinuity of the A1A2/A2H2 and/or A2A3/A3H3 curves. It is possible that use of various atrial sites,16 3 or more extrastimuli, or pharmacological intervention could have revealed discontinuity in some of the patients with smooth AVN curves.
Clinical Implications
It has been well established that total elimination or
modification of the slow pathway, to the extent that repetitive AVN
reentry cannot be induced, is an acceptable therapeutic end point that
portends a good prognosis.6 13 21 22 23 24 However, the end
point is less distinct when the AVN conduction curves do not
demonstrate a classic jump at the transition from the fast to slow
pathway conduction. After successful ablation,
A2H2max might shorten
significantly in group 1 patients, as demonstrated by Tai et
al7 and Sheahan et al.2 In this study,
however, the postablation
A2H2max did reveal a trend
to decrease, although the difference was noted to be statistically
insignificant. The anterograde AVN ERP and AVNWCL also remained
unchanged after ablation in this group. Because
A3H3max is the only
electrophysiological parameter
that shortened in a greater magnitude, it may be shown that
A3H3max is a good (if not
better) indicator compared with
A2H2max in portending a
successful outcome for ablation. It is hoped that this approach will
facilitate the ablation procedure in patients with smooth
A1A2/A2H2
curves who otherwise have typical AVNRT. Finally, the study suggests
that a decrease of
100 to 150 ms in
A3H3max may be indicative
of clinical success. This merits further study in a large patient
population.
| Acknowledgments |
|---|
Received June 23, 1998; revision received September 25, 1998; accepted October 9, 1998.
| References |
|---|
|
|
|---|
2.
Sheahan RG, Klein GJ, Yee R, Le Feuvre CA, Krahn AD.
Atrioventricular node reentry with "smooth" AV node
function curves: a different arrhythmia substrate?
Circulation. 1996;93:969972.
3.
Hariman RJ, Gomes JAC, El-Sherif N.
Catecholamine-dependent atrioventricular
nodal reentrant tachycardia. Circulation. 1983;67:681686.
4. Sung RJ, Waxman HL, Saksena S, Juma Z. Sequence of retrograde atrial activation in patients with dual atrioventricular nodal pathways. Circulation. 1981;64:10531067.
5.
Keim S, Werner P, Jazayeri M, Akhtar M, Tchou P.
Localization of the fast and slow pathways in
atrioventricular nodal reentrant
tachycardia by intraoperative ice mapping.
Circulation. 1992;86:919925.
6. Jackman WM, Beckman KJ, McClelland JH, Wang X, Friday KJ, Roman CA, Moulton KP, Twidale N, Hazlitt HA, Prior ML, Oren J, Overholt ED, Lazzara R. Treatment of supraventricular tachycardia due to atrioventricular nodal reentry by radiofrequency catheter ablation of slow-pathway conduction. N Engl J Med. 1992;327:313318.[Abstract]
7.
Tai CT, Chen SA, Chiang CE, Lee SH, Wen ZC,
Chiou CW, Ueng KC, Chen YJ, Yu WC, Huang JL, Chang MS. Complex
electrophysiological characteristics in
atrioventricular nodal reentrant
tachycardia with continuous
atrioventricular node function curves.
Circulation. 1997;95:25412547.
8. Tchou PJ, Cheng YN, Mowrey K, Efimov IR, Wagoner DRV, Mazgalev TN. Relation of the atrial input sites to the dual atrioventricular nodal pathways: crossing of conduction curves generated with posterior and anterior pacing. J Cardiovasc Electrophysiol. 1997;8:11331144.[Medline] [Order article via Infotrieve]
9.
Natale A, Klein G, Yee R, Thakur R. Shortening of fast
pathway refractoriness after slow pathway ablation: effects of
autonomic blockade. Circulation. 1994;89:11031108.
10.
Wellens HJJ, Duren DR, Liem KL, Lie KI. Effects of
digitalis in patients with paroxysmal atrioventricular
nodal tachycardia. Circulation. 1975;52:779788.
11. Kuo CT, Lauer MR, Young C, Hou CJ, Liem LB, Yu J, Sung RJ. Electrophysiologic significance of discrete slow potentials in patients with dual AV node physiology: implications for radiofrequency ablation of slow pathway conduction. Am Heart J. 1996;131:490498.[Medline] [Order article via Infotrieve]
12. Josephson ME. Supraventricular tachycardias. In: Clinical Cardiac Electrophysiology: Techniques and Interpretations. Philadelphia, Pa: Lea & Febiger; 1993:181274.
13.
Haissaguerre M, Gaita F, Fischer B, Commenges D,
Montserrat P, d'Ivernois C, Lemetayer P, Warin JF. Elimination of
atrioventricular nodal reentrant
tachycardia using discrete slow potentials to guide
application of radiofrequency energy. Circulation. 1992;85:21622175.
14. Strickberger SA, Daoud E, Niebauer M, Williamson BD, Man KC, Hummel JD, Morady F. Effects of partial and complete ablation of the slow pathway on fast pathway properties in patients with atrioventricular nodal reentrant tachycardia. J Cardiovasc Electrophysiol. 1994;5:645649.[Medline] [Order article via Infotrieve]
15. Huycke EC, Lai WT, Nguyen NX, Keung EC, Sung RJ. Role of intravenous isoproterenol in the electrophysiologic induction of atrioventricular node reentrant tachycardia in patients with dual atrioventricular node pathways. Am J Cardiol. 1989;64:11311137.[Medline] [Order article via Infotrieve]
16.
Ross DL, Brugada P, Bar FWHM, Vanagt EJDM, Werner I,
Farre J, Wellens HJJ. Comparison of right and left atrial
stimulation in demonstration of dual atrioventricular
nodal pathways and induction of intranodal reentry.
Circulation. 1981;64:10511058.
17.
Denes P, Wu D, Dhingra RC, Chuquimia R, Rosen KM.
Demonstration of dual AV nodal pathways in patients with paroxysmal
supraventricular tachycardia.
Circulation. 1973;48:549555.
18. Rosen KM, Mehta A, Miller RA. Demonstration of dual atrioventricular nodal pathways in man. Am J Cardiol. 1974;33:291294.[Medline] [Order article via Infotrieve]
19. Paparella N, Alboni P, Pirani R, Cappato R, Tomasi AM, Matoni A. Effects of autonomic blockade on dual atrioventricular nodal pathways pattern. J Electrocardiol. 1986;19:269274.[Medline] [Order article via Infotrieve]
20. Sung RJ, Elser B, McAllister RG Jr. Intravenous verapamil for termination of reentrant supraventricular tachycardias. Ann Intern Med. 1980;93:682689.
21. Lindsay BD, Chung MK, Gamache ML, Luke RA, Schechtman KB, Osborn JL, Cain ME. Therapeutic end points for treatment of atrioventricular node reentrant tachycardia by catheter-guided radiofrequency current. J Am Coll Cardiol. 1993;22:733740.[Abstract]
22. Li HG, Klein GJ, Stites HW, Zardini M, Morillo CA, Thakur RK, Yee R. Elimination of slow pathway conduction: an accurate indicator of clinical success after radiofrequency atrioventricular node modification. J Am Coll Cardiol. 1993;22:18491853.[Abstract]
23.
Kay GN, Epstein AE, Dailey SM, Plumb VJ. Selective
radiofrequency ablation of the slow pathway for the treatment of
atrioventricular nodal reentrant
tachycardia: evidence for involvement of perinodal
myocardium within the reentrant circuit.
Circulation. 1992;85:16751688.
24.
Langberg JJ, Leon A, Borganelli M, Kalbfleisch SJ,
El-Atassi R, Calkins H, Morady F. A randomized, prospective comparison
of anterior and posterior approaches to radiofrequency catheter
ablation of atrioventricular nodal reentry
tachycardia. Circulation. 1993;87:15511556.
This article has been cited by other articles:
![]() |
D. G Katritsis and A. J. Camm Classification and differential diagnosis of atrioventricular nodal re-entrant tachycardia. Europace, January 1, 2006; 8(1): 29 - 36. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |